Claims
- 1. A monoclonal antibody that binds to estrogen receptor α (ER α) when phosphorylated at Serine 118 in the N-terminal domain (residues 1 to 150 of SEQ ID NO: 1), but does not bind ER α when not phosphorylated at this position, wherein said antibody is obtainable from hybridoma cell line ATCC Accession No. PTA-3606, PTA-3607, or PTA-3608.
- 2. A hybridoma cell line producing the monoclonal antibody of claim 1.
- 3. The hybridoma cell line of claim 2, wherein said cell line is ATCC Accession No. PTA-3606, PTA-3607, or PTA-3608.
- 4. A method for detecting phosphorylated ER α in a biological sample, said method comprising the steps of:
(a) contacting a biological sample suspected of containing phosphorylated ER α with the monoclonal antibody of claim 1 under conditions suitable for formation of an antibody-antigen complex; and (b) detecting the presence of said complex in said sample, wherein the detection of said complex indicates the presence of phosphorylated ER α (Ser118) in said sample.
- 5. The method of claim 5, wherein said biological sample is taken from a subject suspected of having cancer.
- 6. A method for profiling ER α activation in a test tissue suspected of involving altered ER α activity, said method comprising the steps of:
(a) contacting said test tissue with at least one detectable monoclonal antibody of claim 1 under conditions suitable for formation of an antibody-antigen complex; (b) detecting the presence of said complex in said test tissue, wherein the presence of said complex indicates the presence of phosphorylated ER α (Ser118) in said test tissue; and (c) comparing the presence of phosphorylated ER α detected in step(b) with the presence of phosphorylated ER α in a control tissue, wherein a difference in ER α phosphorylation profiles between said test tissue and said control tissue indicates altered ER α activation in said test tissue.
- 7. The method of claim 7, wherein said test tissue is taken from a subject suspected of having cancer.
- 8. A method of identifying a compound which modulates phosphorylation of ER α in a test tissue, said method comprising the steps of:
(a) contacting said test tissue with said compound; (b) detecting the level of phosphorylated ER α in said test tissue of step (a) using a detectable monoclonal antibody of claim 1 under conditions suitable for formation of an antibody-antigen complex; (c) comparing the level of phosphorylated ER α detected in step (b) with the presence of phosphorylated ER α in a control tissue not contacted with said compound, wherein a difference in ER α phosphorylation levels between said test tissue and said control tissue identifies said compound as a modulator of ER α phosphorylation.
- 9. The method of claim 9, wherein said test tissue is taken from a subject suspected of having cancer.
- 10. The method of claim 10, wherein said compound is a ER α inhibitor.
- 11. A kit for the detection of phosphorylated ER α in a biological sample, said kit comprising (a) at least one phospho-ER α (Ser118) monoclonal antibody of claim 1 and (b) at least one secondary antibody conjugated to a detectable group.
RELATED APPLICATIONS
[0001] This application claims priority to U.S.S. No. 60/310,066, filed Aug. 3, 2001, now abandoned.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60310066 |
Aug 2001 |
US |